Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)
Public ClinicalTrials.gov record NCT03654729. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in Patients With First-line mCRC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced by the drug oxaliplatin.
Study identification
- NCT ID
- NCT03654729
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 291 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2018 (Actual)
- Primary completion
- Aug 31, 2020 (Actual)
- Completion
- Aug 31, 2020 (Actual)
- Last update posted
- Dec 17, 2021
2018 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Associates | Fresno | California | 93720 | — |
| Mid Florida Hematology and Oncology Center | Orange City | Florida | 32763 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Willis-Knighton Cancer Center | Shreveport | Louisiana | 71103 | — |
| Mercy Clinic - Cancer & Hematology | Springfield | Missouri | 65804 | — |
| Mercy Clinic Oncology and Hematology | St Louis | Missouri | 63141 | — |
| CHI St Francis Cancer Treatment Center | Grand Island | Nebraska | 68803 | — |
| Hunterdon Hematology Oncology | Flemington | New Jersey | 08822 | — |
| Monter Cancer Center | Lake Success | New York | 11042 | — |
| Montefiore Medical Research | The Bronx | New York | 10461 | — |
| Scott & White Vasicek Cancer Treatment Center | Temple | Texas | 76508 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03654729, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2021 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03654729 live on ClinicalTrials.gov.